Please assess the completion status of the following clinical trial:

Trial Title: Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Recurrent or persistent squamous, adenosquamous or adenocarcinoma of the uterine cervix not amenable to curative treatment with surgery and/or radiotherapy~* No prior therapy (radiation, chemotherapy, hormonal therapy or immunotherapy) for recurrence or persistence. May have received platinum in combination with radiation as part of up-front treatment or adjuvant treatment~* Must have measurable disease as defined by RECIST criteria~* Must have at least one target lesion to assess response~* Performance status of 0 or 1~* Patients with ureteral obstruction must undergo stent or nephrostomy tube placement prior to study entry~* At least 4 weeks must have elapsed since prior treatment~* Age \>= 18 years~* Patients of childbearing potential must have a negative pregnancy test, use effective means of contraception~* Signed informed consent~* Bone marrow function: ANC \>= 1500/ul; platelets \>= 100,000 /ul~* Renal function: creatinine \<= 1,5 X ULN (if \> 1.5 creatinine clearance must be \> 60 ml/min)~* Hepatic function: bilirubin \<= 1.5 X ULN, AST and alkaline phosphatase \<= 2.5 X ULN~* Neurologic function: neuropathy \< CTC grade 1~* Coagulation: PT INR \<= 1.5~Exclusion Criteria:~* Evidence of sepsis or severe infection~* Prior therapy for recurrence~* Patients with serious, non-healing wound, ulcer or bone fracture~* Patients with history or evidence of nervous system disease, including primary brain tumor, brain metastases, seizure not controlled with standard medical therapy, CVA, stroke, TIA or subarachnoid hemorrhage within 6 months of 1st date of treatment on study~* Patients with history of other invasive malignancy (treatment within last 5 years) other than non-melanoma skin cancer~* Patient with clinically significant cardiovascular disease defined as:~* Inadequately controlled hypertension (systolic \> 150 and/or diastolic \> 100 on antihypertensive medications); prior history of hypertensive crisis or hypertensive encephalopathy~* Unstable angina within 6 months of enrollment~* NYHA Grade II or greater congestive heart failure~* Serious cardiac arrythmia requiring medication~* Grade 2 or greater peripheral vascular disease; claudication within 6 months~* History of myocardial infarction within 6 months~* Previously diagnosed coagulopathy, disseminated intravascular coagulopathy, immune thrombocytopenia purpura, thrombotic thrombocytopenia purpura or tumor involving major vessels~* Significant vascular disease: aortic aneurysm, aortic dissection~* Active thromboembolic disease: pulmonary embolism, deep venous thrombosis~* Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to day 1 of study; anticipation of need for major surgical procedure during course of the study~* Minor surgical procedure other than central venous access placement, within 7 days prior to day 1 of study~* Patients with proteinuria - patients with urine protein of 1+ on dipstick or \>=30 mg/dl at baseline should undergo UPCR; patients with UPCR of \>=1.0 should be excluded~* Patients who are pregnant or lactating~* No prior investigational agent within 30 days or planned participation in an experimental drug study~* Patients whose circumstances do not permit completion of study or required follow-up~* Prior therapy with bevacizumab or topotecan. Prior platinum therapy allowed as part of initial treatment~* History of abdominal fistula, GI perforation or intra-abdominal abscess within 6 months prior to study enrollment.~* Known hypersensitivity to any component of bevacizumab

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): Cisplatin 50 mg/m2 IV day 1 of a 21 day cycle~Topotecan 0.75 mg/m2 IV Days 1, 2, 3 of a 21 day cycle~Bevacizumab 15 mg/kg day 1 of a 21 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).